 ATyr Pharma Inc NASDAQ: LIFE has announced positive results from its Phase 1b2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lung disease. In 37 patients, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity. 